Megan Rossi1, David W Johnson2, Mark Morrison3, Elaine M Pascoe4, Jeff S Coombes5, Josephine M Forbes6, Cheuk-Chun Szeto7, Brett C McWhinney8, Jacobus P J Ungerer8, Katrina L Campbell2. 1. School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia; Nephrology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia; megan.rossi@uq.net.au. 2. School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia; Nephrology Department, Princess Alexandra Hospital, Brisbane, Queensland, Australia; 3. Translational Research Institute, Brisbane, Queensland, Australia; Diamantina Institute. 4. School of Medicine. 5. Human Movement and Nutrition Sciences, and. 6. School of Medicine, Translational Research Institute, Brisbane, Queensland, Australia; Mater Research Institute, The University of Queensland, Brisbane, Queensland, Australia; 7. Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China; and. 8. Department of Chemical Pathology, Pathology Queensland, Brisbane, Queensland, Australia.
Abstract
BACKGROUND AND OBJECTIVES: The generation of key uremic nephrovascular toxins, indoxyl sulfate (IS), and p-cresyl sulfate (PCS), is attributed to the dysbiotic gut microbiota in CKD. The aim of our study was to evaluate whether synbiotic (pre- and probiotic) therapy alters the gut microbiota and reduces serum concentrations of microbiome-generated uremic toxins, IS and PCS, in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Predialysis adult participants with CKD (eGFR=10-30 ml/min per 1.73 m(2)) were recruited between January 5, 2013 and November 12, 2013 to a randomized, double-blind, placebo-controlled, crossover trial of synbiotic therapy over 6 weeks (4-week washout). The primary outcome was serum IS. Secondary outcomes included serum PCS, stool microbiota profile, eGFR, proteinuria-albuminuria, urinary kidney injury molecule-1, serum inflammatory biomarkers (IL-1β, IL-6, IL-10, and TNF-α), serum oxidative stress biomarkers (F2-isoprostanes and glutathione peroxidase), serum LPS, patient-reported health, Gastrointestinal Symptom Score, and dietary intake. A prespecified subgroup analysis explored the effect of antibiotic use on treatment effect. RESULTS: Of 37 individuals randomized (age =69±10 years old; 57% men; eGFR=24±8 ml/min per 1.73 m(2)), 31 completed the study. Synbiotic therapy did not significantly reduce serum IS (-2 μmol/L; 95% confidence interval [95% CI], -5 to 1 μmol/L) but did significantly reduce serum PCS (-14 μmol/L; 95% CI, -27 to -2 μmol/L). Decreases in both PCS and IS concentrations were more pronounced in patients who did not receive antibiotics during the study (n=21; serum PCS, -25 μmol/L; 95% CI, -38 to -12 μmol/L; serum IS, -5 μmol/L; 95% CI, -8 to -1 μmol/L). Synbiotics also altered the stool microbiome, particularly with enrichment of Bifidobacterium and depletion of Ruminococcaceae. Except for an increase in albuminuria of 38 mg/24 h (P=0.03) in the synbiotic arm, no changes were observed in the other secondary outcomes. CONCLUSION: In patients with CKD, synbiotics did not significantly reduce serum IS but did decrease serum PCS and favorably modified the stool microbiome. Large-scale clinical trials are justified.
RCT Entities:
BACKGROUND AND OBJECTIVES: The generation of key uremic nephrovascular toxins, indoxyl sulfate (IS), and p-cresyl sulfate (PCS), is attributed to the dysbiotic gut microbiota in CKD. The aim of our study was to evaluate whether synbiotic (pre- and probiotic) therapy alters the gut microbiota and reduces serum concentrations of microbiome-generated uremic toxins, IS and PCS, in patients with CKD. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: Predialysis adult participants with CKD (eGFR=10-30 ml/min per 1.73 m(2)) were recruited between January 5, 2013 and November 12, 2013 to a randomized, double-blind, placebo-controlled, crossover trial of synbiotic therapy over 6 weeks (4-week washout). The primary outcome was serum IS. Secondary outcomes included serum PCS, stool microbiota profile, eGFR, proteinuria-albuminuria, urinary kidney injury molecule-1, serum inflammatory biomarkers (IL-1β, IL-6, IL-10, and TNF-α), serum oxidative stress biomarkers (F2-isoprostanes and glutathione peroxidase), serum LPS, patient-reported health, Gastrointestinal Symptom Score, and dietary intake. A prespecified subgroup analysis explored the effect of antibiotic use on treatment effect. RESULTS: Of 37 individuals randomized (age =69±10 years old; 57% men; eGFR=24±8 ml/min per 1.73 m(2)), 31 completed the study. Synbiotic therapy did not significantly reduce serum IS (-2 μmol/L; 95% confidence interval [95% CI], -5 to 1 μmol/L) but did significantly reduce serum PCS (-14 μmol/L; 95% CI, -27 to -2 μmol/L). Decreases in both PCS and IS concentrations were more pronounced in patients who did not receive antibiotics during the study (n=21; serum PCS, -25 μmol/L; 95% CI, -38 to -12 μmol/L; serum IS, -5 μmol/L; 95% CI, -8 to -1 μmol/L). Synbiotics also altered the stool microbiome, particularly with enrichment of Bifidobacterium and depletion of Ruminococcaceae. Except for an increase in albuminuria of 38 mg/24 h (P=0.03) in the synbiotic arm, no changes were observed in the other secondary outcomes. CONCLUSION: In patients with CKD, synbiotics did not significantly reduce serum IS but did decrease serum PCS and favorably modified the stool microbiome. Large-scale clinical trials are justified.
Authors: Nicole M Isbel; Brian Haluska; David W Johnson; Elaine Beller; Carmel Hawley; Thomas H Marwick Journal: Am Heart J Date: 2006-03 Impact factor: 4.749
Authors: Pavel A Aronov; Frank J-G Luo; Natalie S Plummer; Zhe Quan; Susan Holmes; Thomas H Hostetter; Timothy W Meyer Journal: J Am Soc Nephrol Date: 2011-07-22 Impact factor: 10.121
Authors: Wendy R Russell; Sylvia H Duncan; Lorraine Scobbie; Gary Duncan; Louise Cantlay; A Graham Calder; Susan E Anderson; Harry J Flint Journal: Mol Nutr Food Res Date: 2013-01-24 Impact factor: 5.914
Authors: Jakk Wong; Yvette M Piceno; Todd Z DeSantis; Madeleine Pahl; Gary L Andersen; Nosratola D Vaziri Journal: Am J Nephrol Date: 2014-03-08 Impact factor: 3.754
Authors: Neal B Shah; Andrew S Allegretti; Sagar U Nigwekar; Sahir Kalim; Sophia Zhao; Benjamin Lelouvier; Florence Servant; Gloria Serena; Ravi Ishwar Thadhani; Dominic S Raj; Alessio Fasano Journal: Clin J Am Soc Nephrol Date: 2019-04-08 Impact factor: 8.237
Authors: Carmine Zoccali; Raymond Vanholder; Ziad A Massy; Alberto Ortiz; Pantelis Sarafidis; Friedo W Dekker; Danilo Fliser; Denis Fouque; Gunnar H Heine; Kitty J Jager; Mehmet Kanbay; Francesca Mallamaci; Gianfranco Parati; Patrick Rossignol; Andrzej Wiecek; Gerard London Journal: Nat Rev Nephrol Date: 2017-04-24 Impact factor: 28.314
Authors: Mehmet Kanbay; Emine M Onal; Baris Afsar; Tuncay Dagel; Aslihan Yerlikaya; Adrian Covic; Nosratola D Vaziri Journal: Int Urol Nephrol Date: 2018-05-04 Impact factor: 2.370
Authors: Iara Colombo; Florencia Aiello-Battan; Rosario Elena; Agustina Ruiz; Lucas Petraglia; Carlos G Musso Journal: Ir J Med Sci Date: 2020-11-20 Impact factor: 1.568